Cargando…
Targeting mutations in cancer
Targeted therapies have come to play an increasingly important role in cancer therapy over the past two decades. This success has been made possible in large part by technological advances in sequencing, which have greatly advanced our understanding of the mutational landscape of human cancer and th...
Autores principales: | Waarts, Michael R., Stonestrom, Aaron J., Park, Young C., Levine, Ross L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012285/ https://www.ncbi.nlm.nih.gov/pubmed/35426374 http://dx.doi.org/10.1172/JCI154943 |
Ejemplares similares
-
The hematopoietic saga of clonality in sickle cell disease
por: Stonestrom, Aaron J., et al.
Publicado: (2022) -
Targetable IDH1 mutation identified in a rare case of pancreatic serous cystadenocarcinoma but not a series of serous cystadenomas
por: Zhang, Yuxi, et al.
Publicado: (2022) -
Targeting the vasculature in cardiometabolic disease
por: Boutagy, Nabil E., et al.
Publicado: (2022) -
Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations
por: Jorge, Soledad, et al.
Publicado: (2019) -
Targeting ryanodine receptors to treat human diseases
por: Marks, Andrew R.
Publicado: (2023)